Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

Unipolar depression in adults: Choosing treatment for resistant depression - UpToDate

Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia - Clinical Trials Arena

Full article: Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies

Spotlight on brexpiprazole and its potential in the treatment of schiz

Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning

Biomedicines, Free Full-Text

PDF) The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and asadjunctive treatment in patients with major depressive disorder: An analysis of short-term and long-term studies

Brexpiprazole: A New Treatment Option for Schizophrenia and Major Depressive Disorder - Marija Markovic, Alyssa Gallipani, Krina H. Patel, Megan Maroney, 2017

Frontiers Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study

Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

PDF) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study

Full article: Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study

The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors, Biology Direct

Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia - Clinical Trials Arena

New Drug Product: REXULTI - MPR